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Abstract
A mainstay of strategies to prevent HIV-1 transmission is to use antiretroviral therapy (ART) for
pre-exposure prophylaxis (PrEP). Critical to the design and interpretation of PrEP prevention trials
is the ability to make accurate pharmacological measurements of ART drugs in human genital and
colorectal mucosal tissues, the principal route of HIV transmission. Here, we evaluated two drugs
that are preferentially used for PrEP: tenofovir (TFV) disoproxil fumarate (TDF) and emtricitabine
(FTC). A single oral dose of TDF/FTC (Truvada) was administered to 15 healthy individuals.
Over the next 14 days, TFV and FTC were measured in blood plasma and genital secretions using
a sensitive assay (lower level of quantification, 0.1 ng/ml). The active intracellular phosphorylated
metabolites of these drugs [TFV diphospate (TFV-DP) and FTC triphosphate (FTC-TP)] were
measured in homogenates prepared from rectal, vaginal, and cervical tissues. TFV and FTC were
detected in blood plasma 14 days after administration of a single dose. The area under the
concentration-time curve from 24 hours to 14 days (AUC1–14d) for FTC in genital secretions was
27-fold greater than in blood plasma, whereas the AUC1–14d for TFV was only 2.5-fold greater in
genital secretions than in blood plasma. In rectal tissue, TFV and TFV-DP concentrations were
detectable for 14 days and were 100-fold higher than the concentrations in vaginal and cervical
tissues. Vaginal and cervical tissue concentrations of FTC were 10- to 15-fold higher than in rectal
tissue. Despite high concentrations of FTC in vaginal and cervical tissue, FTC-TP concentrations
in all tissue types were detected for only 2 days after dose. The exposure to TFV, TFV-DP, FTC,
and FTC-TP was wide ranging depending on the type of mucosal tissue. These results demonstrate
the need for detailed pharmacological studies to improve the application of ART for PrEP to
prevent transmission of HIV.
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The HIV epidemic is driven by sexual transmission. An estimated 2.9 million individuals
acquired HIV in 2009 despite a global increase in access to antiretroviral therapy (ART) (1).
About 7000 new infections occur each day worldwide, outstripping the expansion of
treatment availability (1), the decrease in AIDS-related mortality (2), and the decrease in
perinatal transmission (3).
In the last year, the results from several pre-exposure chemopro-phylaxis (PrEP)
intervention trials with ART have demonstrated that PrEP is one approach for preventing
HIV infection. In the CAPRISA 004 trial, the first of these studies, the use of 1% tenofovir
(TFV) gel reduced HIV acquisition in women by 39% (4). This trial was followed by the
Pre-exposure Prophylaxis Initiative (iPrEx) study, in which the daily use of an oral fixed-
dose combination of tenofovir disoproxil fumarate and emtricitabine (TDF/FTC; Truvada)
reduced HIV acquisition by 44% in men who have sex with men (5). In both of these
studies, there was a strong relationship between local exposure to ART in the genital tract
(CAPRISA 004) (6) or systemic exposure via plasma (iPrEx) (7) and reduced HIV
acquisition. Two additional studies, TDF2 (8) and Partners PrEP (9), have demonstrated 67
to 78% protection against HIV acquisition in men and women when daily TDF with or
without FTC is used. However, a similar trial in women using daily dosing with Truvada
(FEM-PrEP) was halted because substantial HIV prevention (that is, >30%) could not be
demonstrated (10). In the Vaginal and Oral Interventions to Control the Epidemic (VOICE)
trial, the oral TDF (without FTC) arm was stopped by the Data Safety and Monitoring Board
because protection from HIV infection was not observed (11). The vastly different outcomes
in these prevention trials, which used identical antivirals and dosing schedules, have many
potential explanations. These agents cannot prevent HIV infection unless critical
concentrations of active metabolites of the ART drugs are achieved in body fluids and in
vulnerable mucosal tissues where HIV-1 infection occurs.
The current study was undertaken for two purposes. First, we wanted to determine the decay
of TFV and FTC over 14 days after a single oral dose, which mimics an intermittently used
dosing strategy before or after sexual intercourse. We aimed to measure the decay of TFV
and FTC in plasma, genital fluids, and genital mucosal tissues to gain insight into dosing
strategies based on sexual practices. There is considerable concern that in some of the PrEP
studies, poor adherence to the daily dosing regimen contributed to the failure of some of the
trials. Second, we wanted to examine the pharmacokinetics (PK) of ART prodrugs and their
active phosphorylated forms in body fluids and vulnerable mucosal tissues.
RESULTS
Subject demographics
Eight male and seven female healthy individuals were enrolled in the study and provided the
required tissue and fluid samples (see Table 1 for subject demographics). The median age of
the male and female subjects was 26 and 22 years, respectively. The median body mass
index (BMI) was 23.5 kg/m2 for the males and 24.8 kg/m2 for the females. Five of the males
and six of the females were Caucasian. All participants tolerated the study medication
without any adverse events. Bleeding associated with the biopsy procedures was minimal
and was controlled at the completion of the biopsy procedure.
Table 2 summarizes the concentrations of TFV and FTC and phosphorylated forms of these
drugs [TFV diphospate (TFV-DP) and FTC triphosphate (FTC-TP), respectively] in each
tissue or fluid at 24 hours after a single oral dose of Truvada (C24h). Table 2 also shows the
area under the concentration-time curve from 24 hours to 14 days (AUC1–14d) calculated
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using noncompartmental linear/logarithmic trapezoidal methods. Figures 1 to 3 illustrate
drug concentrations (median values) over time in six tissues and fluids measured by liquid-
chromatography and mass spectroscopy methods. No cervicovaginal fluid and semen
samples had any below level of quantification (BLQ) values that required imputing
(estimating) for any analyte. Twelve percent of plasma samples, 1% of rectal tissue, 7% of
cervical tissue, and 15% of vaginal tissue samples were imputed for one to two analytes.
Drug concentrations in body fluids and mucosal tissues
Blood plasma—To detect TFV and FTC concentrations for 36 hours after dosing (5, 12),
we developed an assay with 100-fold greater sensitivity than other published methods. Using
this assay, we were able to detect TFV and FTC concentrations in blood plasma up to 14
days after dose in all subjects (see Fig. 1A and Materials and Methods).
The median AUC1–14d for TFV and FTC was 91 and 83 ng·days/ml, respectively. The
median terminal elimination half-life (t1/2), calculated from 7 to 14 days, was 47 hours for
TFV and 49 hours for FTC. Bi-exponential elimination is illustrated in Fig. 1A, with one
elimination rate occurring between 1 and 5 days after dose, and a second occurring between
7 and 14 days after dose.
Cervicovaginal fluid—Concentrations of TFV and FTC in cervicovaginal fluid over 14
days after a single dose are shown in Fig. 1B. These concentrations are similar to our
previous measurements with single and daily dosing in HIV-positive women (13). The
AUC1–14d for TFV and FTC in cervicovaginal fluid was 251 (151 to 1257) and 2445 (2309
to 3631) ng·days/ml, respectively. Compared with TFV, the concentrations of FTC were
much higher throughout the study period. The AUC1–14d ratio of cervicovaginal fluid to
blood plasma for TFV was 2.6 (1.7 to 13.4), whereas for FTC it was 26.8 (25.0 to 43.8).
This demonstrates that FTC concentrations remained high in female genital tract secretions
throughout all time intervals after dosing. The terminal elimination half-life t1/2 of FTC in
cervicovaginal fluid was 40 hours, which was similar to that observed in blood plasma. In
comparison, the terminal elimination half-life t1/2 for TFV in cervicovaginal fluid was 71
hours, which is about 50% longer than that in blood plasma.
Seminal plasma—We measured TFV and FTC concentrations in seminal plasma to
elucidate drug behavior in the male genital tract. Concentrations of TFV and FTC in seminal
plasma are shown in Fig. 1C. TFV concentrations were similar to our previous
measurements with single and daily dosing in HIV-positive men (13). The AUC1–14d of
TFV and FTC in seminal plasma was 91 (51 to 156) and 408 (233 to 586) ng·days/ml,
respectively. As with cervicovaginal fluid, the seminal plasma concentrations of FTC were
much higher than those of blood plasma throughout the study period. The AUC1–14d ratio of
seminal plasma to blood plasma for TFV was 1.0 (0.6 to 1.4) and for FTC was 4.5 (3.3 to
6.1). The terminal elimination half-life t1/2 for TFV and FTC in seminal plasma was similar
to that in blood plasma: 59 and 47 hours, respectively.
Genital mucosal tissues—Once inside mucosal epithelial cells, TFV and FTC are
phosphorylated to their active metabolites, TFV-DP and FTC-TP, respectively. The tissue
concentrations for TFV and TFV-DP are shown in Fig. 2, A and B, and for FTC and FTC-
TP are shown in Fig. 3, A and B. Composite PK parameters of C24h and AUC1–14d are listed
in Table 2.
Rectal tissue—TFV and TFV-DP were both detectable in rectal tissue throughout the 14-
day study period. The AUC1–14d for TFV was 2989 ng·days/g, resulting in a 34-fold
increase in rectal tissue concentration compared with the concentration in blood plasma. The
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AUC1–14d of TFV-DP was 649,502 fmol·days/g. The median concentration of TFV-DP in
rectal tissue homogenates at the end of the first 24-hour period after dosing was 206,950
fmol/g, demonstrating high penetration of this drug into this mucosal site. In these rectal
tissue homogenates, there was a strong log-linear relationship between TFV and TFV-DP
concentrations (r2 = 0.86; P < 0.01). FTC could also be detected in rectal tissue throughout
the 14-day study period. However, the FTC concentration in the rectum was substantially
lower than that for TFV, with a median concentration at 24 hours (C24h) of 124 ng/g and an
AUC1–14d of 266 ng·days/g. FTC-TP (Fig. 3B) was only detected in rectal tissue for 2 days
after dosing. The relationship between FTC and FTC-TP concentrations in this tissue could
not be calculated.
Vaginal tissue—In the female subjects, TFV was detectable in vaginal tissue for up to 10
days after a single dose of Truvada, whereas TFV-DP was detected for the 14 days of the
study. Twenty-four hours after dosing, the median TFV concentration in vaginal tissue was
about 2.5 logs lower than the median TFV concentration in rectal tissue (6.8 versus 1877 ng/
g), and the TFV-DP concentrations were about 2.2 logs lower (1645 versus 206,950 fmol/g).
FTC could be measured for up to 10 days in vaginal tissue and exceeded the blood plasma
FTC concentration by sevenfold. FTC-TP could only be detected in vaginal tissue 24 to 48
hours after the oral dose was given. At 24 hours after dose, the median FTC concentration in
vaginal tissue was about 50% lower than in rectal tissue (63 versus 126 ng/g), and the FTC-
TP concentration was about one log higher than in rectal tissue (63,469 versus 8450 fmol/g).
Cervical tissue—TFV and FTC concentrations in cervical tissue were similar to, but more
variable than, the drug concentrations in vaginal tissue. Similar to vaginal tissue, FTC could
be quantified in cervical tissue for up to 10 days after dosing. The AUC1–14d for FTC was
2495 ng/g, which was four times greater than that for TFV. Similar to vaginal and rectal
tissue, FTC-TP could only be measured in cervical tissue for the first 24 hours after dosing.
Because of a large proportion of undetectable TFV-DP and FTC-TP concentrations in
cervical and vaginal tissues, the relationship between TFV or FTC and their intracellular
metabolites could not be calculated.
DISCUSSION
Antiretroviral drugs when given prophylactically have the potential to prevent the
acquisition of HIV (14). Pre-exposure chemoprophylaxis (PrEP) using TDF with or without
FTC decreases HIV acquisition in animal models when used topically and orally (15–18), in
women when used topically (4), and in men who have sex with men when used orally (5).
However, in two recent trials—using daily doses of TDF combined with FTC (Truvada) in
the FEM-PrEP trial or daily doses of TDF alone in one arm of the VOICE trial—there was
failure to protect women from acquiring HIV (10, 11). In contrast, the Partners PrEP trial in
serodiscordant couples demonstrated 62 and 73% protection with either TDF alone or in
combination with FTC, respectively (9). Last, the TDF2 trial using a daily oral dose of TDF
combined with FTC strongly suggested differential protection based on gender, although the
study was not powered to evaluate gender differences (8). The reason for the different
outcomes of these trials is not known. However, it is possible that differential penetration
and half-life of the antiretroviral agents in different mucosal tissues did not lead to
equivalent protection among all mucosal tissues exposed to HIV, permitting HIV acquisition
in some cases.
We studied the concentrations of TFV, FTC, and their active metabolites in mucosal tissues,
genital secretions, and blood plasma after a single oral dose of the fixed-dose drug
combination TDF/FTC (Truvada) using an ultrasensitive assay (100-fold more sensitive than
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standard published methods) (19–21). Previous work has carefully examined the PK profiles
of TFV and FTC and their active metabolites in the first 24 hours after dosing (13, 22).
Therefore, in our study, sampling began at the 24-hour time point to define the final phase of
decay. We determined that TFV and FTC plasma concentrations could be detected in all
subjects, and quantified in 50% of subjects for 14 days after a single dose of Truvada. The
terminal elimination half-life was 47 hours for TFV and 49 hours for FTC between 7 and 14
days after dosing. These are longer than the 17- and 10-hour terminal elimination half-life
times usually cited for TFV and FTC, respectively (23). Our results may more accurately
reflect the true terminal elimination half-life of the drugs from plasma, because the shorter
half-lives cited in the literature were derived from concentrations measured for up to only 48
hours after dosing. The longer drug elimination half-lives reported here also suggest that
there may be a longer-lived cell population that forms a slowly equilibrating reservoir of
drug. For example, the natural destruction of peripheral blood mononuclear cells (PBMCs)
may release TFV-DP and FTC-TP into the systemic circulation, where these drug
metabolites could be converted back to the parent TFV and FTC drugs. We did not measure
PBMC concentrations in this study, but this could be explored further in future studies. The
long plasma half-lives of TFV and FTC do not help to explain the inconsistent results among
the different PrEP trials.
We report here that the concentrations of TFV and FTC and their respective active
metabolites TFV-DP and FTC-TP varied according to the mucosal tissue type. The TFV
concentration in rectal mucosa was greater and existed longer than the FTC concentration,
whereas the FTC concentration in vaginal and cervical tissue was greater than the TFV
concentration. This differential penetration may provide insight into the variable level of
protection reported with different PrEP drug combinations in diverse populations in the
different trials. TFV, TFV-DP, and FTC could be quantified in mucosal tissues for 10 to 14
days, whereas FTC-TP was only detected for up to 2 days. Data generated during the
development and validation of the assay for detecting TFV, FTC, and their active
metabolites did not suggest that FTC-TP was degraded during tissue processing (18).
Therefore, we propose that FTC-TP (23) has a shorter tissue half-life than does TFV-DP
(23, 24). The reason for the shorter half-life of FTC-TP could be elucidated if the ART
drugs were studied in individual cell populations, which we did not do here because this
would have required quantities of tissue that could not be obtained in a clinical study.
Concentrations of TFV, FTC, TFV-DP, and FTC-TP in human rectal mucosa have not
previously been evaluated (25). The TFV results presented here have been confirmed in two
recently completed trials (MTN 001 and MTN 006) (26, 27). The prolonged high
concentration of TFV and its active metabolite TFV-DP in rectal tissues is consistent with
the benefit provided by TFV in the rectal challenge macaque model (15) and the iPrEx
clinical trial in human subjects (5). The more limited concentrations of FTC and its
metabolite FTC-TP in the rectal mucosa may explain the limited protective effects of FTC in
the macaque model (15).
The penetration of ART into seminal plasma and vaginal and cervical tissues, although
comparable or superior to penetration in blood plasma, was 10 to 100 times lower than
penetration of rectal tissue. Our earlier reports from studies of single and daily dosing of
TDF and FTC in semen (22) and cervicovaginal fluids (13) yielded similar results. Limited
vaginal challenge studies in macaques and humanized mice (28, 29) demonstrated partial to
complete efficacy with TFV ± FTC treatment. However, there is a paucity of data regarding
genital tract tissue concentrations of ART drugs in these preclinical animal model systems.
The failure of daily oral ART to prevent HIV acquisition in the FEM-PrEP and VOICE trials
raises the possibility that the concentrations of TFV and FTC in animal studies may be
different from those achieved in humans, and that the concentrations achieved in humans are
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not sufficient to prevent HIV acquisition. The differing results of these trials also reinforce
the need for in-depth preclinical pharmacological analyses to establish biological plausibility
before beginning large-scale clinical studies.
The concentrations of ART achieved in female genital tract tissue, reported here and in our
previous studies (13), suggest that standard TDF/FTC oral dosing may not be sufficient to
prevent HIV acquisition. In the CAPRISA 004 study, TFV concentrations in the vaginal
lumen 24 hours after coitally dependent dosing were estimated to be about 105 ng/ml, which
would result in TFV-DP concentrations of 102 to 103 fmol/mg based on vaginal and cervical
biopsy data from this study and others (6, 17, 30, 31). These TFV-DP concentrations are 100
times greater than what we observed in vaginal and cervical tissue after oral dosing (but are
similar to what we observed in rectal tissue) (6). Finally, recent clinical data on the shedding
of HIV RNA in the genital tract of women may also provide some indirect evidence of ART
activity in mucosal tissue. More than 50% of HIV-infected women on ART (including two
nucleoside reverse transcriptase inhibitors) with undetectable HIV RNA in their blood
plasma had detectable HIV RNA in their genital secretions (32). The ART regimens are too
variable in these cohorts to isolate the effect of individual drugs or select combination
regimens based on local HIV replication. However, these data suggest that some ART drugs
may not achieve sufficient concentrations in mucosal tissues to completely suppress local
replication of HIV and, accordingly, may not be sufficient to prevent acquisition of HIV.
Our study provides new insights into using ART for PrEP to prevent HIV infection. Vaginal
acquisition of HIV may require a stronger barrier to infection than that provided by oral
dosing with a TDF/FTC combination. The results of the current study and recent PrEP
clinical trials indicate that more work needs to be done to elucidate the appropriate
pharmacological barrier required to prevent HIV acquisition. More detailed pharmacological
studies are required to better evaluate whether ART can prevent HIV acquisition and for the
optimal management of HIV prevention trials that use antiviral agents prophylactically to
prevent HIV infection.
MATERIALS AND METHODS
Study design and subject selection
This 14-day, open-label, PK study in healthy HIV-negative female and male volunteers was
conducted between October 2008 and May 2010 at the University of North Carolina at
Chapel Hill (UNC). The UNC Biomedical Institutional Review Board approved the study,
and all subjects provided written informed consent before any study procedure
(ClinicalTrials.gov identifier NTC00080410). Subjects were eligible to participate if they
were healthy, were between the ages of 18 and 50 years, and had a BMI between 18 and 30
kg/m2 with a total body weight of ≥50 kg. Females were required to be premenopausal with
regular menstrual cycles (between 26 and 35 days), have an intact uterus and cervix, and not
be pregnant or breastfeeding. Males were required to not participate in a conception process.
Subjects were excluded on the basis of any evidence of kidney disease; a positive urine drug
screen; the presence of a sexually transmitted infection; or infection with HIV, hepatitis B
virus, or hepatitis C virus. Subjects were excluded for any abnormal screening laboratory
results, any clinically significant abnormality on physical examination, or any clinical
condition that would interfere with study procedures. Subjects were required to stop all
medications 7 days before and herbal supplements 14 days before study medication
administration, and medications could not be restarted until study completion. Females were
required to be off hormonal contraceptives for a minimum of 30 days or depo-
medroxyprogesterone for 120 days before enrollment. Subjects were limited to five
cigarettes per day and were allowed up to 1 g of acetaminophen per day. Subjects were
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instructed to abstain from sexual intercourse and the use of intravaginal (females) or
intrarectal (males) devices from 72 hours before dosing until study discharge.
Screening procedures occurred within the 28 days before study medication dosing.
Comprehensive laboratory studies, including a complete blood count with differential, liver
function tests, serum chemistries, hepatitis B and C virus serology panels, urinalysis, and
serum pregnancy testing, and sexually transmitted infection evaluations were performed at
the screening visit. Sexually transmitted infection evaluations included testing for
gonorrhea, Chlamydia, trichomonas (Aptima Combo 2 and Aptima TV ASR Kits; Gen-
Probe Inc.), and syphilis. Herpes simplex virus type 2 antibody (Focus Diagnostics) was
measured if indicated by the presence of suspected herpetic lesions on exam. All subjects
underwent anonymous HIV testing with a standard HIV-1/2 ELISA (enzyme-linked
immunosorbent assay) (Genetic Systems HIV-1/HIV-2 Plus O EIA) with pooled HIV-1
polymerase chain reaction (PCR) testing (Roche COBAS AmpliPrep/COBAS TaqMan
HIV-1 Test, v.1.0). All testing was performed in the McLendon Laboratories of UNC
Hospitals or in the UNC Sexually Transmitted Diseases Cooperative Research Center
Microbiology Core Lab.
Study visits
Subjects received a single dose of 300 mg of TDF and 200 mg of FTC administered as a
single-dose tablet of Truvada in the morning of the baseline study visit. All subjects had
paired blood plasma and cervicovaginal fluid or semen collected on days 1, 2, 5, 7, 10, and
14 after dose. Subjects were sequentially assigned to undergo mucosal tissue biopsy on days
1 and 5, 2 and 10, or 7 and 14 after dose (two men and two women at each time point). All
mucosal tissue collection procedures were performed in the outpatient setting. Females
underwent two cervical and two vaginal biopsies at each of the two paired time points.
Males underwent lower gastrointestinal (about 10 cm from anal verge) biopsies at each of
the same two paired time points. Males were requested to follow a low-fiber diet for 3 days
before biopsy dates and a clear liquid diet for 12 hours before the procedure.
Sample collection
Blood plasma—Whole blood was obtained with EDTA collection tubes (BD Diagnostics)
and centrifuged at 1300g at 4°C for 10 min. The resulting blood plasma was aliquoted into
labeled cryovials and stored at −80°C until analysis.
Vaginal and cervical specimens—Clinicians collected cervicovaginal fluid samples via
direct aspiration with a volumetric aspiration device (13) before speculum insertion. After
collection, cervicovaginal fluid was transferred to labeled cryovials and stored at −80°C
until analysis.
Vaginal and cervical tissues were collected by biopsy. Briefly, subjects were placed in the
dorsal lithotomy position. After speculum insertion, the vaginal fornices and the entire
cervix were prepped with 2% viscous lidocaine solution (lidocaine hydrochloride), and then
were additionally anesthetized with topical 20% benzocaine spray (HurriCaine, Beutlich
Pharmaceuticals). Vaginal tissue biopsies were obtained at either the left or the right vaginal
fornix. Cervical biopsies were obtained at either the 3- or the 9-o’clock position. Biopsies at
the second time point were obtained at the opposite location. About 3 mm × 3 mm × 1 mm
specimens were obtained at both the vaginal and the cervical sites with Baby Tischler
forceps (Cooper Surgical). Samples were placed in separate labeled screw-capped
polypropylene tubes, immediately snap-frozen in liquid nitrogen, and stored at −80°C until
analysis.
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Seminal plasma and rectal tissue—Semen samples were collected in the research
center. Whole semen samples were allowed to liquefy at room temperature for at least 45
min before centrifugation at 2500g at 10°C for 15 min. Seminal plasma was transferred to
labeled cryovials and stored at −80°C until analysis. Rectal tissue samples were obtained
through flexible sigmoidoscopy at one of the UNC Gastrointestinal (GI) Procedure Suites
according to standard GI procedures. Conscious sedation was offered but declined by all
participants. Once biopsy sites were identified, the sites were rinsed with sterile irrigation
water with diluted simethicone oral drops before collection. Ten single rectal tissue biopsies
were collected with Radial Jaw 4 Large Capacity Forceps (Boston Scientific), pooled into a
single cryovial, and immediately snap-frozen in liquid nitrogen. All specimens were stored
at −80°C until analysis.
Sample processing
TFV and FTC were extracted from 70 μl of blood plasma and 50 μl of cervicovaginal fluid
or seminal plasma with acetonitrile protein precipitation. TFV, TFV diphosphate (TFV-DP),
FTC, and FTC-TP were extracted from tissue samples with a protein precipitation and
homogenization process on a Precellys 24 tissue homogenizer (Bertin Technologies).
Individual cell populations were not isolated from the tissue. Internal standards were
isotopically labeled TFV and FTC for the protein precipitation of blood plasma,
cervicovaginal fluid, and seminal plasma. Isotopically labeled TFV-DP and FTC-TP were
also used as internal standards for tissue analysis. Samples were analyzed on an Agilent
6460 triple quadruple liquid chromatography–tandem mass spectrometry (LC-MS/MS)
system (Agilent Technologies) with electrospray ionization. The ion transition for TFV was
288+ to 176+, the ion transition for FTC was 248+ to 130+, the transition for TFV-DP was
448+ to 270+, and the ion transition for FTC-TP was 488+ to 130+. Blood plasma,
cervicovaginal fluid, and seminal plasma analytes were separated on a reversed-phase
Waters Atlantis T3 C18 (2.1 × 100 mm, 3 μm) high-performance liquid chromatography
(HPLC) column with an isocratic mobile phase of 2.5% MeCN with 0.1% formic acid/
97.5% water with 0.1% formic acid and a flow rate of 0.3 ml/min with a column temperature
of 35°C. Tissue analytes were separated on a Waters Xbridge C18 (2.1 × 20 mm, 5 μm)
column in series with a Thermo Scientific BioBasic AX (50 × 2.1 mm, 5 μm) column.
Having the columns in series provided a mixed-mode reverse phase and ion exchange
separation to simultaneously quantify phosphorylated and unphosphorylated analytes. An
initial mobile phase of 20 mM ammonium acetate went to 100% (40% acetonitrile/60% 100
mM ammonium acetate, pH 9.45) over a period of 2 min. The mobile phase was then held at
100% (40% acetonitrile/60% 100 mM ammonium acetate, pH 9.45) for an additional 3.2
min. The columns were then recovered in 20 mM ammonium acetate for 6.5 min. The flow
rate for the method was 0.3 ml/min with a column compartment temperature of 35°C. The
analytical concentration range for TFV and FTC in blood plasma was 0.1 to 500 ng/ml, and
in cervicovaginal fluid and seminal plasma was 2 to 1000 ng/ml. TFV, TFV-DP, FTC, and
FTC-TP concentration ranges in tissue were 0.1 to 1000 ng/ml. Standards, quality controls
(QCs), and blanks for cervicovaginal fluid, seminal plasma, blood plasma, and biopsy
samples were prepared with equivalent blank matrix obtained from external suppliers and
UNC Hospital donors. All blank material was obtained from screened donors that were free
of drugs that could potentially interfere with assay results. Blank samples were evaluated for
analyte signals and compared to lower level of quantification (LLOQ) response to assess
contamination of sample preparation media and matrices. Inspection of blanks allowed each
sample assay to be examined for sources of contamination that would affect LLOQ
accuracy.
Two separately prepared standard curves were used to bracket all samples, QCs, and blanks.
QC samples at three concentration levels representing the low, middle, and high end of the
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calibration curve were distributed among the samples and blanks to ensure accurate
quantitation throughout the analysis. Acceptance criteria for the assay were based on those
from the Food and Drug Administration (FDA) for bioanalytical assays. QC concentrations
had to calculate to ±15% of their nominal value to be accepted. Standard concentrations
were back-calculated from the calibration regression and their values had to be ±15% from
their nominal concentration, with the exception of the LLOQ, which required ±20%. In
order for sample concentration values to be reported, 75% of all standards and 66% of all
QCs had to be acceptable. For vaginal biopsies, FTC QCs had an average (±SD) accuracy of
102.0 ± 7.5, TFV had an average accuracy of 98.4 ± 6.5, TFV-DP had an average accuracy
of 105.0 ± 7.2, and FTC-TP had an average accuracy of 94.2 ± 5. For cervical biopsies,
FTC, TFV, FTC-TP, and TFV-DP QCs had accuracies of 102.4 ± 7.0, 100.0 ± 8.4, 100.2 ±
5.8, and 99.7 ± 12.3, respectively. For rectal biopsies, FTC, TFV, FTC-TP, and TFV-DP
QCs had accuracies of 97.5 ± 6.8, 98.6 ± 7.3, 103.4 ± 11.1, and 100.4 ± 5.6, respectively.
Cervical biopsy samples weighed 5 to 17 mg, vaginal biopsy samples weighed 1 to 30 mg,
and rectal tissue biopsy samples weighed 11 to 33 mg. There was no confounding of tissue
biopsy weight with drug concentration. For seminal plasma, FTC and TFV QCs had
accuracies of 98.3 ± 5.6 and 92.5 ± 4.6. Blood plasma FTC and TFV QCs had accuracies of
107.8 ± 8.3 and 98.4 ± 7.9. Cervicovaginal fluid FTC and TFV QCs had accuracies of 100.5
± 4.2 and 104.1 ± 5.4. The %RSD for the standards ranged from 10.3 to 4.0%. The %RSD
for the QCs ranged from 12.3 to 4.1%.
Data analysis
PK parameters were estimated with noncompartmental methods (Phoenix WinNonlin,
Pharsight). We imputed those concentrations that were detectable but below the limit of
quantification as 50% of the lower limit of quantification for that analyte and matrix.
Concentrations that were below the limit of detection were imputed as “0.” The AUC1–14d
after dose was estimated with the log-linear trapezoidal method, and visual curve stripping
was performed for estimation of the terminal elimination slope. Individual PK profiles were
obtained for blood plasma, cervicovaginal fluid, and seminal plasma. A composite approach
was used to estimate tissue PK parameters by analyzing geometric mean concentration data.
To compare cervicovaginal fluid, seminal plasma, and tissue exposure to blood plasma, we
calculated C24h and AUC1–14d ratios. A tissue density of 1.04 g/ml was used to convert ng/g
to ng/ml for this purpose (33). We generated descriptive statistics using WinNonlin.
Demographic data and PK parameters are presented as median values (25th to 75th
percentile).
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Concentrations of TFV and FTC in blood plasma, cervicovaginal fluid, and semen. (A to C)
Median concentrations (ng/ml) of the ART drugs TFV and FTC in (A) blood plasma, (B)
cervicovaginal fluid, and (C) seminal plasma for 14 days after a single dose of a TDF/FTC
drug combination (vertical lines representing interquartile ranges). Samples were analyzed
by liquid chromatography and mass spectroscopy methods.
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Concentrations of TFV and TFV-DP in mucosal tissues. (A and B) Median concentrations
of (A) TFV (ng/g) and (B) TFV-DP (fmol/g) in rectal (black), vaginal (gray), and cervical
(white) mucosal tissues over 14 days after a single dose of TDF/FTC (vertical lines
represent interquartile ranges). Samples were analyzed by liquid chromatography and mass
spectroscopy methods.
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Concentrations of FTC and FTC-TP in mucosal tissues. (A and B) Median concentrations of
(A) FTC (ng/g) and (B) FTC-TP (fmol/g) in rectal (black), vaginal (gray), and cervical
(white) mucosal tissues over 14 days after a single dose of TDF/FTC (vertical lines
represent interquartile ranges). Samples were analyzed by liquid chromatography and mass
spectroscopy methods.
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Table 1
Demographics of study participants.
Parameter Males (n = 8) Females (n = 7)
Age (years)* 26 (19–37) 22 (21–25)
Race
African American 1 (12%) 1 (14%)
Asian 2 (25%) 0
White 5 (63%) 6 (86%)
Weight (kg)* 74.6 (65–88.9) 71.2 (61.4–87.8)
BMI (kg/m2)* 23.5 (18.8–28.1) 24.8 (21.2–28.6)
*
Median (range).
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